Navigation Links
Collaborative Preclinical Efficacy Studies Suggest a New Target for Drug Addiction Treatment
Date:3/14/2012

MENLO PARK, Calif., March 14, 2012 /PRNewswire/ -- In preclinical studies, researchers at SRI International and Astraea Therapeutics have recently evaluated the role of a new drug receptor target that shows promise for the treatment of drug addiction.

This potential new drug target belongs to a class of receptors called the nicotinic acetylcholine receptors (nAChRs). One subtype of nAChRs, called alpha4beta2, is a well-known target for nicotine's addictive effects and the therapeutic effect of the smoking cessation drug varenicline.  SRI researchers are now studying another, lesser-known subtype, called alpha3beta4 nAChR, which has recently shown to play a role in the addictive properties of cocaine, morphine, and nicotine.

Using AT-1001, a highly selective alpha3beta4 compound developed by Astraea Therapeutics, SRI researchers found that addiction processes could be disrupted. In preliminary studies, AT-1001 also reduced nicotine withdrawal symptoms such as anxiety. 

Because addictive drugs act on the brain's "reward circuit," many people compulsively take them despite their harmful consequences.  Feelings of pleasure are caused by the release of brain chemicals, or neurotransmitters, and their increased activity in the brain reward circuit.  The key neurotransmitter in the reward circuit is dopamine, which produces changes in addictive behavior.  Researchers speculate that disruption of the alpha3beta4 nAChR system using highly selective drugs such as AT-1001 may interrupt this reward circuitry.

"Currently, there are no therapeutics approved to treat addiction to stimulants such as cocaine, so it is intriguing to find a promising drug receptor target and to see that AT-1001 can indeed affect phenomena that are thought to be deeply tied to the addictive nature of cocaine and other drugs of abuse," said Taline Khroyan, Ph.D., Senior Behavioral Pharmacologist in SRI's Center for Health Sciences.


'/>"/>

SOURCE SRI International
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. CellCyte Genetics Corp. Enters Collaborative Research Agreement With Cleveland Clinic Foundation to Qualify Stem Cell Delivery in Damaged Heart Tissue
2. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
3. Rib-X Pharmaceuticals Renews Collaborative Agreement with the Medical Research Council
4. The Leukemia & Lymphoma Society and Anjin Group Announce Multi-Year Collaborative Research Agreement
5. ACORN Presents Findings of Collaborative Metastatic Colorectal Cancer Research
6. BASF Officially Launches the Collaborative Advanced Research Initiative at Harvard University
7. CellCyte Genetics Signs Collaborative Agreement With Northwestern Universitys Feinberg School of Medicine to Perform Disease Model Outcome Study of CellCytes CCG-TH30 Product Candidate
8. Two Hutchinson Center Scientists Receive a Total of $16.7 Million for Collaborative Stem Cell Research
9. iThemba Pharmaceuticals (Pty) Ltd and Pyxis Discovery B.V. Announce Collaborative Agreement to Offer a Combined Service Offering
10. Rib-X Pharmaceuticals Enters into Collaborative Agreement on Delafloxacin with Massachusetts General Hospital
11. Medco, State of Illinois and Community Retail Pharmacies Launch Wired Collaborative Solution to Close Critical Medication-Related Gaps in Healthcare, Improving Outcomes and Lowering Costs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 MultiCell Technologies, Inc. (OTC Bulletin Board: ... application concerning composition of matter, biological targets, mechanism of ... death.  This patent application describes a ... molecules (VSRNAs) which interfere with the basic homeostatic cellular ...
(Date:1/15/2014)... 15, 2014 Reportlinker.com announces that a ... its catalogue: PharmaPoint: ... Market Analysis to 2022 ... - India Drug Forecast and Market Analysis ...
(Date:1/15/2014)... Ohio , Jan. 15, 2014  A novel wearable injector ... easy and painless for patients to self-inject prescription drugs in ... disorders, including cancer, blood diseases, autoimmune deficiencies, and genetic disorders.  ... to grow to $220B by 2018, according to analysts.   Many ...
Breaking Medicine Technology:MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2
... Orthopedics, Inc., the world leader in PyroCarbon orthopedic ... Modular Total Shoulder System. This newly designed system ... shoulder arthroplasty with one implant system. ... in collaboration with Joseph Abboud, M.D, Phillip Duke, ...
... Calif., Sept. 2 NewCardio (OTC Bulletin Board: ... Vincent Renz, Jr., NewCardio,s President and CEO, purchased 128,000 shares ... two weeks following the Company,s filing of its SEC Form ... 30, 2010. "As discussed on our August ...
Cached Medicine Technology:Ascension Orthopedics Receives FDA Approval for TITAN™ Modular Total Shoulder System 2NewCardio CEO Increases Equity Position 2NewCardio CEO Increases Equity Position 3NewCardio CEO Increases Equity Position 4
(Date:7/9/2014)... risen dramatically in Western societies. One frequently cited reason ... have fewer infections than previous generations, thereby delaying maturation ... at Sahlgrenska Academy, University of Gothenburg, monitored children until ... immune system in relation to allergic disease. All of ... Gtaland Region, half of them on farms that produced ...
(Date:7/8/2014)... kidney donors enjoy similar longevity and cardiovascular health as ... published in the American Journal of Transplantation . ... considering donation and the transplant professionals caring for them. ... by individuals aged 55 years and older has become ... disease, and heart disease, the removal of a kidney ...
(Date:7/8/2014)... Defense Advanced Research Projects Agency (DARPA) awarded Lawrence ... to develop an implantable neural device with the ... brain to help restore memory, DARPA officials announced ... understanding that memory is a process in which ... information, store it and retrieve it. Certain types ...
(Date:7/8/2014)... found to be three times higher when auditors were ... auditors present, according to a study in a major ... "Quantification of the Hawthorne effect in hand hygiene compliance ... study," published today on-line in the BMJ Quality ... Srigley, who did the study as part of her ...
(Date:7/8/2014)... discovered a biomarker that could give expecting mothers and ... predict that a pregnant woman may develop preeclampsia, at ... , Preeclampsia is a cardiovascular disorder generally occurring late ... creating immediate and potentially lifelong risks to both mother ... in the urine, and is typically diagnosed in the ...
Breaking Medicine News(10 mins):Health News:Study finds kidney donation safe for healthy older adults 2Health News:DARPA selects Lawrence Livermore to develop world's first neural device to restore memory 2Health News:DARPA selects Lawrence Livermore to develop world's first neural device to restore memory 3Health News:Health-care worker hand hygiene rates increase three-fold when auditors visible 2Health News:Health-care worker hand hygiene rates increase three-fold when auditors visible 3Health News:UI researchers find early predictor for preeclampsia 2Health News:UI researchers find early predictor for preeclampsia 3
... Actor Joe Pantoliano,reveals a personal history of ... untreated bipolar disorder, in a guest blog entry, ... on Mental,Illness (NAMI)., Pantoliano,s entry comes during ... days before the opening of his latest film, ...
... shows , TUESDAY, Oct. 9 (HealthDay News) -- U.S. ... to a treatment for the hereditary, progressive neurological disorder ... molecule called C2-8 appears to reduce HD-related neurological damage ... team from the MassGeneral Institute for Neurological Disorders (MIND), ...
... anxiety, low control doubles recurrent heart attack risk, study finds ... doubles the risk that someone who has had a heart ... finds. , Other studies have shown that workplace stress boosts ... anxieties with recurrent heart attacks and other major events, the ...
... scientists have developed a potentially novel way to fight ... of radiation inside cancer cells, unlike current treatments that ... the outside and cause unwanted side effects. , ... new radiation delivery system proved able to specifically target ...
... 9 The March of,Dimes congratulates Mario R. Capecchi, ... Smithies, D.Phil., FRS, former recipients of the,March of Dimes ... in Physiology or Medicine. The Nobel Committee announced ... of principles for introducing specific gene,modifications in mice by ...
... Oct. 9 Health plans are expecting premium,rate increases ... last,year,s expectation of 8.2%. This is the fourth consecutive ... conducted this survey in September of 2007. The survey,contained ... nationwide. Separately, the survey notes that the East ...
Cached Medicine News:Health News:Actor Joe Pantoliano Discloses Depression; Talks About His Latest Movie and His Sensitive Side 2Health News:Molecule Promising Against Huntington's Disease 2Health News:Stressful Jobs Hard on the Heart 2Health News:Stressful Jobs Hard on the Heart 3Health News:Inside job: new radioactive agents for colon cancer work inside cells 2Health News:Nobel Honors 3 Former March of Dimes Prize Recipients 2
... over 20 years of experience in ... the Life Sciences, the Freedom EVO ... possibilities for expansion according to future ... software, Freedom EVOware, each system is ...
... EVO Clinical is an open platform for clinical ... in deck sizes of 75, 100, 150 ... instrument for your laboratory space and throughput requirements. ... features to allow new applications and to evolve ...
... liquid handling system that ... of up to three ... the same worksurface. Offered ... solutions for targeted applications ...
... The AccelNet Laboratory Automation Network ... clinical chemistry systems, an automated sample ... manager to create a single, powerful ... ideal for laboratories that need a ...
Medicine Products: